BioStem Technologies (BSEM)
Manufacturer of placental-tissue allografts for wound care and surgical applications.
Something off on this page? Send us feedback.
Manufactures placental and perinatal tissue allografts for wound-care and surgical settings, selling through physician-office, hospital, agent, distributor, and GPO/IDN channels. Its range spans Neox, Clarix, VENDAJE, and American Amnion AC, with BioTissue supplying key acquired products during technology transfer.
Manufactures placental and perinatal tissue allografts for advanced wound care and surgical applications, including the Neox, Clarix, VENDAJE, and American Amnion AC portfolios. Its BioRetain, CryoTek, and SteriTek platforms process or preserve tissue for uses such as wound coverings, barriers, conduits, and cushions. Product revenue is recognized when products ship to customers.
Serves hospitals, ambulatory surgical centers, physician offices, wound-care centers, mobile providers, and long-term-care settings across the United States, using a hospital sales team alongside agents, distributors, and GPO/IDN agreements. The acquired Neox and Clarix business expanded the hospital channel, while BioTissue manufactures those products during technology transfer.
Most products are marketed as human-tissue products for homologous use, making product claims and sales tied to regulatory classification, payer coverage, and site-of-care rules. The right to manufacture and commercialize Neox and Clarix depends on a license from BioTissue.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $7.0M · Total debt $1.2M · Total assets $48.8M · Shareholders' equity $27.6M
- Revenue
- $7.9M
- Operating income
- −$8.4M
- Net income
- −$9.0M
No dividends on record.
| Insiders10 holders · as of Aug 28, 2026 | 16.77% | 2.99M shares | |
| Otherremainder | 83.23% | 14.86M shares |
17.85M company shares as of Sep 3, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Vurst Andrew Smith-VanInsiderdirector, 10 percent owner, officer: Chief Operating Officer | 8.53% | 1.52M | Form 4filed Aug 14, 2026 ↗ |
Jason MatuszewskiInsiderdirector, 10 percent owner, officer: Chief Executive Officer | 7.16% | 1.28M | Form 4filed Aug 14, 2026 ↗ |
Michael A. FortunatoInsiderofficer: Chief Accounting Officer | 0.36% | 64,430 | Form 4filed Aug 20, 2026 ↗ |
Brandon PoeInsiderofficer: Chief Financial Officer | 0.32% | 56,368 | Form 4filed Aug 20, 2026 ↗ |
Kenneth Howard Jr WarringtonInsiderdirector | 0.18% | 32,234 | Form 4filed Aug 28, 2026 ↗ |
| See all 10 → | |||
Form 4 — an insider's transaction report
Insider tradesForm 4
No open-market trades in the last 12 months.
- Organogenesis
Placental allografts and skin substitutes in advanced wound care.
- MiMedx
Placental allografts overlap across wound care and surgery.
- Smith & Nephew (ADR)
Hospital wound management and orthopedic procedure overlap.
- Integra LifeSciences
Tissue matrices compete for complex and chronic wound cases.
- Bioventus
Orthobiologics overlap in surgical allograft procedures.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| BioStem Technologies | $3.58 | +0.56% | $60.1M | — | — | — | −84.0% |
| Organogenesis | $1.68 | +0.56% | $214.9M | — | — | 0.5 | −56.7% |
| MiMedx | $4.56 | +1.00% | $663.2M | 113.8 | 107.3 | 1.9 | −34.7% |
| Smith & Nephew (ADR) | $28.71 | +0.12% | $12.04B | 19.0 | — | 1.9 | +3.7% |
| Integra LifeSciences | $16.88 | +0.42% | $1.31B | — | 6.6 | 0.8 | +0.8% |
| Bioventus | $14.37 | +0.10% | $973.5M | 18.7 | 17.8 | 1.7 | +3.8% |
| Median | 19.0 | 17.8 | 1.7 | +0.8% |